Free Trial

Virax Biolabs Group (VRAX) Competitors

Virax Biolabs Group logo
$0.87 +0.01 (+0.74%)
Closing price 07/8/2025 03:33 PM Eastern
Extended Trading
$0.88 +0.01 (+1.57%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VRAX vs. SNSE, XFOR, SNPX, CSCI, PHXM, BCDA, NLSP, GLYC, LSB, and ADXN

Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Sensei Biotherapeutics (SNSE), X4 Pharmaceuticals (XFOR), Synaptogenix (SNPX), COSCIENS Biopharma (CSCI), PHAXIAM Therapeutics (PHXM), BioCardia (BCDA), NLS Pharmaceutics (NLSP), GlycoMimetics (GLYC), LakeShore Biopharma (LSB), and Addex Therapeutics (ADXN). These companies are all part of the "pharmaceutical products" industry.

Virax Biolabs Group vs. Its Competitors

Virax Biolabs Group (NASDAQ:VRAX) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Virax Biolabs Group has higher revenue and earnings than Sensei Biotherapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virax Biolabs Group$10K376.02-$6.06MN/AN/A
Sensei BiotherapeuticsN/AN/A-$30.16M-$23.00-0.39

In the previous week, Virax Biolabs Group's average media sentiment score of 0.00 equaled Sensei Biotherapeutics'average media sentiment score.

Company Overall Sentiment
Virax Biolabs Group Neutral
Sensei Biotherapeutics Neutral

Virax Biolabs Group has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.

Virax Biolabs Group currently has a consensus price target of $3.00, indicating a potential upside of 246.26%. Sensei Biotherapeutics has a consensus price target of $90.00, indicating a potential upside of 896.68%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Virax Biolabs Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Sensei Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Virax Biolabs Group's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Virax Biolabs GroupN/A N/A N/A
Sensei Biotherapeutics N/A -66.72%-57.10%

Summary

Virax Biolabs Group beats Sensei Biotherapeutics on 6 of the 11 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAX vs. The Competition

MetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.73M$2.87B$5.47B$8.95B
Dividend YieldN/A2.45%5.25%4.04%
P/E RatioN/A20.8026.9920.11
Price / Sales376.02286.31428.71119.81
Price / CashN/A41.1936.8257.86
Price / Book0.697.487.985.56
Net Income-$6.06M-$55.04M$3.16B$248.40M
7 Day Performance0.76%2.44%2.38%4.67%
1 Month Performance-13.45%1.90%2.17%6.64%
1 Year Performance-22.64%4.35%33.81%21.31%

Virax Biolabs Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAX
Virax Biolabs Group
2.8416 of 5 stars
$0.87
+0.7%
$3.00
+246.3%
-27.8%$3.73M$10K0.005
SNSE
Sensei Biotherapeutics
4.1692 of 5 stars
$8.75
+2.0%
$90.00
+928.6%
-28.9%$11.03MN/A-0.3840
XFOR
X4 Pharmaceuticals
4.6406 of 5 stars
$1.90
-0.3%
$72.33
+3,717.1%
-90.5%$10.97M$2.56M0.8880Gap Up
SNPX
Synaptogenix
1.1573 of 5 stars
$7.85
+29.8%
$14.00
+78.3%
+86.6%$10.91MN/A-0.784High Trading Volume
CSCI
COSCIENS Biopharma
N/A$3.42
+0.6%
N/AN/A$10.77M$9.59M-0.5920Gap Down
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58M$32.66M0.0049
BCDA
BioCardia
3.9598 of 5 stars
$2.04
+4.4%
$25.00
+1,128.5%
-21.3%$10.54M$60K-0.8740Positive News
NLSP
NLS Pharmaceutics
N/A$2.88
-0.7%
N/A+1,192.5%$10.37MN/A0.006
GLYC
GlycoMimetics
1.1457 of 5 stars
$0.16
-6.6%
N/A-99.4%$10.00M$10K-0.3450High Trading Volume
LSB
LakeShore Biopharma
0.3442 of 5 stars
$1.06
+3.4%
N/AN/A$9.82M$80.82M0.00773News Coverage
Positive News
Gap Up
ADXN
Addex Therapeutics
2.82 of 5 stars
$9.21
-2.2%
$30.00
+225.9%
+13.3%$9.76M$460K-27.0730Positive News
Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:VRAX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners